PARP-1 inhibitor
and PARP-1 inhibitor DPQ on glioma by a Ca 2+ -Mg 2+ -endonuclease pathway
... CME inhibitor aurintricarboxylic acid decreased the glioma cell death induced by H 2 O 2 or the PARP-1 inhibitor, ...the PARP-1 inhibitor, and the CME may be a useful ...
7
PARP 1 inhibitor monotherapy and combination therapy in a preclinical mouse model of Brca2 mutant breast cancer
... study of treatment and outcome for 1,065 breast cancer patients for which we examined factors correlating with cancer recurrence. We found that infection of surgical wounds after surgery for primary disease positively ...
49
Cytotoxicity of anticancer drugs and PJ-34 (poly(ADP-ribose)polymerase-1 (PARP-1) inhibitor) on HL-60 and Jurkat cells
... of PARP-1 (a component of the DNA single-strand break (SSB) repair machinery), unrepaired SSB lesions are converted into DNA DSB dur- ing DNA replication and require activation of homolo- gous recombination ...
7
Comparative study of the binding characteristics to and inhibitory potencies towards PARP and in vivo antidiabetogenic potencies of taurine, 3-aminobenzamide and nicotinamide
... of PARP activation in pancreatic islet cell damage by STZ can be ascertained from the circulating levels of both insulin and glucose, with the type of dia- betes being a determined by the dose of STZ adminis- ...
15
Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis
... by PARP-1 [3, 81, 96] and at high concentrations, the PARP-1/2 inhibitor Veliparib can promote the mislo- calization of nuclear FUS-GFP to the cytoplasm ...dismutase 1) [69]. ...
15
PARP-1 activity is required for the reconsolidation and extinction of contextual fear memory
... that PARP-1 positively regulates the formation of long-term memory (LTM); however, the roles of PARP-1 in memory processes, especially processes after retrieval, remain ...for ...
15
Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
... poly-[ADP-ribose]-polymerase 1 (PARP-1) activity for ...the PARP-1 inhibitor Olaparib to increase the number of cytotoxic ...after PARP inhibitor addition in the ...
12
Original Article Function and mechanism of combined PARP-1 and BRCA genes in regulating the radiosensitivity of breast cancer cells
... combined PARP-1 and BRCA genes in regulating the radiosensitivity of breast cancer cells by poly ADP-ribose polymerase-1 (PARP-1) inhibitor 3-amion benzamide (3- AB) onBRCA ...
6
<p>First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of a Neuroprotective Poly (ADP‐ribose) Polymerase‐1 Inhibitor, JPI-289, in Healthy Volunteers</p>
... of PARP-1 activation has been reported as a potential ther- apeutic option for providing neuroprotection by diminish- ing the infarct size, shrinking edema volume, and attenuating neurovascular unit damage ...
11
Evaluation of Melanin Targeted Radiotherapy in Combination with Radiosensitizing Drugs for the Treatment of Melanoma
... [11]. PARP-1 inhibitors improve the efficiency and selectivity of DNA-damaging agents [12], indicating their potential as components of combination ...in PARP-1-deficient mice and cell lines, ...
10
Synthesis and evaluation of a radioiodinated tracer with specificity for poly(ADP-ribose) polymerase-1 (PARP-1) in vivo
... polymerase 1 (PARP-1) is a nuclear protein responsible for various cellular processes including repair of single-stranded DNA breaks (SSB), cell division, gene transcription and apoptosis ...
42
A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage
... a 1:1 ratio, and fractionated to enrich for chromatin-bound ...between 1 and 50 are plotted in Fig. 1D. In this graph, a median ratio >1 suggests a preferential enrichment of the protein in ...
7
Noncleavable poly(ADP ribose) polymerase 1 regulates the inflammation response in mice
... caspase inhibitor–treated animals, namely through NF-κB transactivation of cytotoxic ...that PARP-1 cleavage may be required for NF-κB transcriptional ...the PARP-1 cleavage was already ...
11
An update on PARP inhibitors for the treatment of cancer
... cal demonstration of PARPi activity in the BRCA mutation– associated cancers (Figure 4). In this study, 60 patients with refractory cancers were recruited to evaluate the pharma- cokinetics and pharmacodynamics of ...
10
Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer
... phase 1/1b trial in patients with ovarian/BC harboring BRCA1/2 mutations ...phase 1 study evaluating the safety and efficacy of paclitaxel in combination with olaparib in metastatic ...
11
Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer
... (PARP) inhibitor Olaparib has been recently approved by FDA as the first monotherapy to treat BRCA-mutated advanced ovarian cancer ...[14]. PARP is involved in surveillance and maintenance of genome ...
14
Resolution of the cellular proteome of the nucleocapsid protein from a highly pathogenic isolate of porcine reproductive and respiratory syndrome virus identifies PARP 1 as a cellular target whose interaction is critical for virus biology
... The interaction of N protein and the host cell has been supported by several studies showing the association of this viral protein with cellular proteins including those involved in nuclear import such as importin- a and ...
11
BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor
... dual inhibitor, has been designed, which competitively occupies the BRD4 pocket structure by binding to acetylated lysine and subsequently deploy transcription protein complexes and RNA polymerase, which inhibits ...
13
RING domain–deficient BRCA1 promotes PARP inhibitor and platinum resistance
... (construct 1, SI00096313 and construct 2, SI02654575) and AllStars Negative Control siRNA (scram- bled control) from ...siRNA 1 (J-003873-09) and siRNA 2 ( J-003873-10) were obtained from ...
14
PARP inhibitor combination therapy.
... Combinations of vascular endothelial growth factor receptor inhibitors (VEGFRi) with several chemotherapies have already been licensed for treatment in metastatic colorectal cancer, renal cancer, and advanced non- ...
42